• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary therapy. >Treatment Satisfaction During Routine Treatment with the SQ?-Standardised Grass Allergy Immunotherapy Tablet: A Non-interventional Observational Study
【24h】

Treatment Satisfaction During Routine Treatment with the SQ?-Standardised Grass Allergy Immunotherapy Tablet: A Non-interventional Observational Study

机译：SQ？-标准草过敏免疫治疗片常规治疗期间的治疗满意度：一项非干预性观察研究

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionTherapy with the SQ?-standardised grass sublingual immunotherapy (SLIT)-tablet has been shown to be efficacious and well-tolerated in a large clinical development programme. The objective of this study was to investigate patients’ satisfaction with treatment by the SQ? grass SLIT-tablet during routine application. MethodsIn the setting of a non-interventional, open-label, observational study, patients with allergic rhinoconjunctivitis were started on the SQ? grass SLIT-tablet 4–5?months before the grass pollen season and were followed until the end of the season. Treatment satisfaction was assessed by patients completing the Treatment Satisfaction Questionnaire for Medication (TSQM II, German version 1.4) before and after the grass pollen season. Compliance and changes in subjective well-being were also assessed. ResultsData of 271 patients treated with the SQ? grass SLIT-tablet by 117 allergists in Germany were analysed. The TSQM score for global satisfaction was (mean?±?standard deviation) 79.40?±?19.98 after 6–9?months of therapy, with the highest scores for the dimensions side effects (92.89?±?16.49) and convenience (88.19?±?14.33), followed by effectiveness (70.74?±?25.20). Treatment effect was assessed by the treating physician as very good or good in 83.1% of patients. The subjective well-being of the patients compared with the previous years was assessed as improved by 87.8% of the patients at the end of the study. ConclusionsGlobal satisfaction measured with the TSQM in patients treated with the SQ? grass SLIT-tablet was high, with the highest scores in the dimensions side effects and convenience, followed by effectiveness, and increased between 3?months and 6–9?months of treatment initiation. FundingALK-Abelló Arzneimittel GmbH
机译：简介在大型临床开发计划中，使用SQ ？标准化草舌舌免疫疗法（SLIT）片剂进行治疗已被证明是有效且耐受性良好的。这项研究的目的是调查患者对常规应用SQ ？草SLIT片剂治疗的满意度。方法在一项非干预性，开放标签，观察性研究的背景下，过敏性鼻结膜炎患者在草花粉季节前4-5个月开始于SQ ？草SLIT-片剂上开始治疗，并进行随访直到赛季结束在草花粉季节之前和之后，通过填写《药物治疗满意度调查表》（TSQM II，德语版1.4）的患者来评估治疗满意度。还评估了依从性和主观幸福感的变化。结果分析了德国117名过敏者对271例接受SQ ？草SLIT片治疗的患者的数据。在治疗6–9个月后，TSQM总体满意度得分为（平均值±标准偏差）79.40±19.98，在副作用方面（92.89±16.49）和便利性（88.19？）最高。 ±？14.33），其次是有效性（70.74？±？25.20）。主治医师认为83.1％的患者的治疗效果非常好。在研究结束时，与往年相比，患者的主观幸福感提高了87.8％。结论用SQ ？草SLIT片剂治疗的患者用TSQM测得的总体满意度高，在副作用和便利性方面得分最高，其次是有效性，并且在3个月至3个月之间有所提高开始治疗的6-9个月。资金ALK-AbellóArzneimittel GmbH

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号